8058057 1675932 1333369 1850298 7764055 8142256 1323952 1320012 7935322 9062121 1358431 1976136 11062478 1657846 10691864 8390992 1649696 8063712 1963303 9328845 1846338 1980425 7678889 8294050 7712479 2553990 9125189 1720047 8004758 9748545 1309224 - Search Results

Year	Number of Results
1989	1
1990	10
1991	16
1992	10
1993	21
1994	17
1995	11
1996	8
1997	5
1998	3
1999	1
2000	3
2001	1
2003	1
2004	1
2006	2
2007	1
2008	1
2009	1
2013	1
2023	0

1

Reduced phosphorylation of topoisomerase II in etoposide-resistant human leukemia K562 cells.

Ritke MK, Allan WP, Fattman C, Gunduz NN, Yalowich JC. Ritke MK, et al. Mol Pharmacol. 1994 Jul;46(1):58-66. Mol Pharmacol. 1994. PMID: 8058057

2

Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II.

Cole SP, Chanda ER, Dicke FP, Gerlach JH, Mirski SE. Cole SP, et al. Cancer Res. 1991 Jul 1;51(13):3345-52. Cancer Res. 1991. PMID: 1675932

3

Dissociation of cytotoxicity and DNA cleavage activity induced by topoisomerase II-reactive intercalating agents in hamster-human somatic cell hybrids.

Glisson BS, Killary AM, Merta P, Ross WE, Siciliano J, Siciliano MJ. Glisson BS, et al. Cancer Chemother Pharmacol. 1992;31(2):131-8. doi: 10.1007/BF00685100. Cancer Chemother Pharmacol. 1992. PMID: 1333369

4

Cross-resistance of an amsacrine-resistant human leukemia line to topoisomerase II reactive DNA intercalating agents. Evidence for two topoisomerase II directed drug actions.

Zwelling LA, Mayes J, Hinds M, Chan D, Altschuler E, Carroll B, Parker E, Deisseroth K, Radcliffe A, Seligman M, et al. Zwelling LA, et al. Biochemistry. 1991 Apr 23;30(16):4048-55. doi: 10.1021/bi00230a032. Biochemistry. 1991. PMID: 1850298

5

Altered DNA topoisomerase II in multidrug resistance.

Beck WT, Danks MK, Wolverton JS, Granzen B, Chen M, Schmidt CA, Bugg BY, Friche E, Suttle DP. Beck WT, et al. Cytotechnology. 1993;11(2):115-9. doi: 10.1007/BF00749000. Cytotechnology. 1993. PMID: 7764055 Review.

6

Altered stability of etoposide-induced topoisomerase II-DNA complexes in resistant human leukaemia K562 cells.

Ritke MK, Roberts D, Allan WP, Raymond J, Bergoltz VV, Yalowich JC. Ritke MK, et al. Br J Cancer. 1994 Apr;69(4):687-97. doi: 10.1038/bjc.1994.131. Br J Cancer. 1994. PMID: 8142256 Free PMC article.

7

Effects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase II: Influence of the C-8 fluorine group.

Robinson MJ, Martin BA, Gootz TD, McGuirk PR, Osheroff N. Robinson MJ, et al. Antimicrob Agents Chemother. 1992 Apr;36(4):751-6. doi: 10.1128/AAC.36.4.751. Antimicrob Agents Chemother. 1992. PMID: 1323952 Free PMC article.

8

Cytotoxicity of quinolones toward eukaryotic cells. Identification of topoisomerase II as the primary cellular target for the quinolone CP-115,953 in yeast.

Elsea SH, Osheroff N, Nitiss JL. Elsea SH, et al. J Biol Chem. 1992 Jul 5;267(19):13150-3. J Biol Chem. 1992. PMID: 1320012 Free article.

9

A cisplatin-resistant murine leukemia cell line exhibits increased topoisomerase II activity.

Barret JM, Calsou P, Larsen AK, Salles B. Barret JM, et al. Mol Pharmacol. 1994 Sep;46(3):431-6. Mol Pharmacol. 1994. PMID: 7935322

10

Quinolones share a common interaction domain on topoisomerase II with other DNA cleavage-enhancing antineoplastic drugs.

Elsea SH, Westergaard M, Burden DA, Lomenick JP, Osheroff N. Elsea SH, et al. Biochemistry. 1997 Mar 11;36(10):2919-24. doi: 10.1021/bi962488f. Biochemistry. 1997. PMID: 9062121

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

Search Page

Search Results